DHEA, DHEA-S

Written By Guest User
EXOSOMES (9).png
 

Presentation by: Wei (Adelyn) Tsai

Reviewed by: Thia Hanania & Greg Hollenbeck

Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) are neurosteroids. They are involved in many different neurological pathways that promote the generation and survival of neurons (Maninger et al., 2010). These neuroprotective effects make DHEA and DHEA-S the research focus on treatments for a number of neurological and neuropsychiatric diseases, including depression, schizophrenia, and dementia. DHEA has been extensively studied and is demonstrated to be useful for depression (Peixoto et al., 2014), while some studies also provided evidence for the efficacy of DHEA for schizophrenia (Strous et al., 2003) and dementia (Wolkowitz et al., 2003). With these emerging evidence, DHEA may be a useful brain supplement to improve brain health and functions.

 
 

Further studies: 

1. DHEA/S ratio to other hormones as biomarkers for neurological/neuropsychiatric diseases

2. Assess the efficacy and establish guidelines for DHEA monotherapy or adjunctive therapy for neurological/neuropsychiatric diseases

3. Larger, longer clinical studies on dementia, schizophrenia, etc.

Reference for introduction:

Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Synthia, H. (2010). Neurobiological and Neuropsychiatric Effects of DHEA and DHEA-s. NIH Public Access, 30(1), 65–91. https://doi.org/10.1016/j.yfrne.2008.11.002.Neurobiological

Peixoto, C., Devicari Cheda, J., Nardi, A., Veras, A., & Cardoso, A. (2014). The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review. Current Drug Targets, 15(9), 901–914. https://doi.org/10.2174/1389450115666140717111116

Strous, R. D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., & Weizman, A. (2003). Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia. Archives of General Psychiatry, 60(2), 133. https://doi.org/10.1001/archpsyc.60.2.133

Wolkowitz, O. M., Kramer, J. H., Reus, V. I., Costa, M. M., Yaffe, K., Walton, P., Raskind, M., Peskind, E., Newhouse, P., Sack, D., De Souza, E., Sadowsky, C., & Roberts, E. (2003). DHEA treatment of Alzheimer’s disease: A randomized, double-blind, placebo-controlled study. Neurology, 60(7), 1071–1076. https://doi.org/10.1212/01.WNL.0000052994.54660.58 

  • Reference in presentation:

    • Schverer, M., Lanfumey, L., Baulieu, E. E., Froger, N., & Villey, I. (2018). Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases. Pharmacology and Therapeutics, 191, 190–206. https://doi.org/10.1016/j.pharmthera.2018.06.011

    • Stárka, L., Dušková, M., & Hill, M. (2015). Dehydroepiandrosterone: A neuroactive steroid. Journal of Steroid Biochemistry and Molecular Biology, 145, 254–260. https://doi.org/10.1016/j.jsbmb.2014.03.008 

    • Maggio, M., De Vita, F., Fisichella, A., Colizzi, E., Provenzano, S., Lauretani, F., Luci, M., Ceresini, G., Dall’Aglio, E., Caffarra, P., Valenti, G., & Ceda, G. P. (2015). DHEA and cognitive function in the elderly. The Journal of Steroid Biochemistry and Molecular Biology, 145, 281–292. https://doi.org/10.1016/j.jsbmb.2014.03.014

    • Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Synthia, H. (2010). Neurobiological and Neuropsychiatric Effects of DHEA and DHEA-s. NIH Public Access, 30(1), 65–91. https://doi.org/10.1016/j.yfrne.2008.11.002.Neurobiological

    • Kessler, R. C. (2012). The costs of depression. Psychiatric Clinics, 35(1), 1-14.

    • Barnes, T. R., Leeson, V. C., Mutsatsa, S. H., Watt, H. C., Hutton, S. B., & Joyce, E. M. (2008). Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. The British journal of psychiatry, 193(3), 203-209.

    • Castro, D. M., Dillon, C., Machnicki, G., & Allegri, R. F. (2010). The economic cost of Alzheimer's disease: Family or public-health burden?. Dementia & Neuropsychologia, 4(4), 262-267.

    • Schizophrenia - Symptoms and causes - Mayo Clinic. (n.d.). Retrieved August 23, 2020, from https://www.mayoclinic.org/diseases-conditions/schizophrenia/symptoms-causes/syc-20354443

    • The Cost of Dementia Care in 2018. (n.d.). Retrieved August 23, 2020, from https://www.alzheimers.net/the-cost-of-dementia-care 

    • Fishback, J. A., Robson, M. J., Xu, Y.-T., & Matsumoto, R. R. (2010). Sigma receptors: Potential targets for a new class of antidepressant drug. Pharmacology & Therapeutics, 127(3), 271–282. https://doi.org/10.1016/j.pharmthera.2010.04.003

    • Kubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., & Maes, M. (2011). In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(3), 744–759. https://doi.org/10.1016/j.pnpbp.2010.08.026

    • Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011). A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(3), 676–692. https://doi.org/10.1016/j.pnpbp.2010.05.004

    • Steckler, T., Holsboer, F., & Reul, J. M. H. M. (1999). Glucocorticoids and depression. Best Practice & Research Clinical Endocrinology & Metabolism, 13(4), 597–614. https://doi.org/10.1053/beem.1999.0046

    • Briley, M., & Chantal, M. (2011). The importance of norepinephrine in depression. Neuropsychiatric Disease and Treatment, 9. https://doi.org/10.2147/NDT.S19619

    • Dunlop, B. W., & Nemeroff, C. B. (2007). The Role of Dopamine in the Pathophysiology of Depression. Archives of General Psychiatry, 64(3), 327. https://doi.org/10.1001/archpsyc.64.3.327

    • Peixoto, C., Devicari Cheda, J., Nardi, A., Veras, A., & Cardoso, A. (2014). The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review. Current Drug Targets, 15(9), 901–914. https://doi.org/10.2174/1389450115666140717111116

    • Balu, D. T. (2016). The NMDA Receptor and Schizophrenia (pp. 351–382). https://doi.org/10.1016/bs.apha.2016.01.006

    • Abi-Dargham, A., & Moore, H. (2003). Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia. The Neuroscientist, 9(5), 404–416. https://doi.org/10.1177/1073858403252674

    • Misiak, B., Frydecka, D., Loska, O., Moustafa, A. A., Samochowiec, J., Kasznia, J., & Stańczykiewicz, B. (2018). Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis. Psychoneuroendocrinology, 89, 92–102. https://doi.org/10.1016/j.psyneuen.2018.01.007

    • Gallagher, P., Watson, S., Smith, M., Young, A., & Ferrier, I. (2007). Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophrenia Research, 90(1–3), 258–265. https://doi.org/10.1016/j.schres.2006.11.020

    • Harris, D. S., Wolkowitz, O. M., & Reus, V. I. (2001). Movement Disorder, Memory, Psychiatric Symptoms and Serum DHEA Levels in Schizophrenic and Schizoaffective Patients. The World Journal of Biological Psychiatry, 2(2), 99–102. https://doi.org/10.3109/15622970109027500

    • Ritsner, M., Gibel, A., Ram, E., Maayan, R., & Weizman, A. (2006). Alterations in DHEA metabolism in schizophrenia: Two-month case-control study. European Neuropsychopharmacology, 16(2), 137–146. 

    • Strous, R. D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., & Weizman, A. (2003). Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia. Archives of General Psychiatry, 60(2), 133. https://doi.org/10.1001/archpsyc.60.2.133

    • Quinn, T. A., Robinson, S. R., & Walker, D. (2018). Dehydroepiandrosterone (DHEA) and DHEA Sulfate: Roles in Brain Function and Disease. In Sex Hormones in Neurodegenerative Processes and Diseases. InTech. https://doi.org/10.5772/intechopen.71141

    • Chen, L., Dai, X.-N., & Sokabe, M. (2006). Chronic administration of dehydroepiandrosterone sulfate (DHEAS) primes for facilitated induction of long-term potentiation via sigma 1 (σ1) receptor: Optical imaging study in rat hippocampal slices. Neuropharmacology, 50(3), 380–392. https://doi.org/10.1016/j.neuropharm.2005.10.015

    • Bastianetto, S., Ramassamy, C., Poirier, J., & Quirion, R. (1999). Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Molecular Brain Research, 66(1–2), 35–41. https://doi.org/10.1016/S0169-328X(99)00002-9

    • Tamagno, E., Guglielmotto, M., Bardini, P., Santoro, G., Davit, A., Di Simone, D., Danni, O., & Tabaton, M. (2003). Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiology of Disease, 14(2), 291–301. https://doi.org/10.1016/S0969-9961(03)00131-1

    • Wolkowitz, O. M., Kramer, J. H., Reus, V. I., Costa, M. M., Yaffe, K., Walton, P., Raskind, M., Peskind, E., Newhouse, P., Sack, D., De Souza, E., Sadowsky, C., & Roberts, E. (2003). DHEA treatment of Alzheimer’s disease: A randomized, double-blind, placebo-controlled study. Neurology, 60(7), 1071–1076. https://doi.org/10.1212/01.WNL.0000052994.54660.58

Guest User
Previous

Metformin, Mechanism of Action
Next

ARA290